Why GLP-1 Marketing Is Under the Microscope Right Now
If you're marketing a GLP-1 product — compounded semaglutide, tirzepatide, or any branded weight loss program built around these drugs — 2026 is the year you cannot afford to look away from your marketing copy.
The FDA issued more than 30 warning letters to telehealth and compounded drug companies in the first half of 2026 alone. That pace exceeds the combined total from the previous three years. Regulators aren't just glancing at product labels anymore. They are systematically reviewing websites, landing pages, email campaigns, and paid ad copy.
The brands caught in this wave aren't all reckless operators. Many are growth-stage companies where the marketing team moved faster than the compliance function could keep up. A single landing page with one flagged phrase can be enough to trigger a formal enforcement action.
This article breaks down every major violation category the FDA has cited in GLP-1 and telehealth enforcement actions, explains why each is problematic, and gives you compliant language to use instead.
This article focuses on marketing communications — websites, ads, emails, and social content. It does not address prescription drug labeling, clinical trial requirements, or compounding pharmacy regulations, which are separate and more complex. Consult a regulatory attorney for advice specific to your situation.
What the FDA Actually Said About Compounded GLP-1s
To understand why so many brands are receiving warning letters, you need to understand the regulatory sequence that led here.
Semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) were added to the FDA's drug shortage list in 2022 and 2023 respectively. Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are permitted to prepare copies of drugs that are in shortage — which opened a legal window for compounded semaglutide and tirzepatide to be prescribed and dispensed.
What the law did not do was authorize those compounded versions as FDA-approved drugs. Compounded drugs bypass the full NDA approval process. They are not equivalent to brand-name drugs from a regulatory standpoint, even if they contain the same active ingredient. This distinction — widely misunderstood in marketing — is the source of most of the enforcement activity we're seeing.
In 2025, Novo Nordisk and Eli Lilly both petitioned the FDA to remove semaglutide and tirzepatide from the shortage list as supply normalized. The FDA agreed on semaglutide in early 2025, meaning compounding exemptions began expiring. This put thousands of compounding-dependent telehealth companies in a difficult position — and many responded by doubling down on aggressive marketing to capture patients before the window closed. Regulators noticed.
Even if you are operating within the compounding exemption, your marketing language must accurately reflect the regulatory status of what you're selling. Claims that imply FDA approval, equivalence to brand-name drugs, or disease treatment authorization are where brands consistently get into trouble.
Violation #1: Sameness Claims ("Same as Ozempic")
This is the single most common trigger in GLP-1 warning letters. In multiple enforcement actions, the FDA explicitly called out marketing language that implied or stated that a compounded product was the same as — or equivalent to — a brand-name FDA-approved drug.
This framing suggests the compounded product is therapeutically equivalent to Ozempic. It is not. Compounded drugs have not undergone the clinical trials, manufacturing inspections, or approval processes that FDA-approved drugs have. Implying equivalence misrepresents the regulatory status of the product and misleads consumers.
Variations of this pattern that have also drawn FDA scrutiny include:
- "Contains the same semaglutide found in Ozempic"
- "Medically equivalent to Wegovy — without the waitlist"
- "Generic semaglutide" (compounded semaglutide is not a generic — generics undergo an abbreviated NDA process; compounded drugs do not)
- "Biosimilar semaglutide" (biosimilars are a specific regulatory category; compounded versions do not qualify)
The safest practice is to avoid mentioning brand names entirely in comparative claims. If you reference Ozempic or Wegovy, do so only in a factual educational context — never in a way that implies your product is a substitute or equivalent.
Violation #2: Unsubstantiated Outcome Claims
The second major category involves specific weight-loss outcomes presented as typical results without adequate substantiation. The FTC's updated endorsement guidelines (2023) and the FDA's requirements for drug marketing both require that outcome claims be supported by competent and reliable scientific evidence — and that they reflect typical results, not cherry-picked best cases.
This claim makes two problems simultaneously: it states a specific outcome without evidence that it reflects typical results, and it adds a guarantee, which under FTC rules requires substantiation that results are achievable for most people. The clinical trial data on GLP-1s shows meaningful average weight loss, but results vary significantly by individual, dose, duration, and lifestyle factors.
Other outcome claim patterns to avoid:
- Specific pound amounts without a disclaimer ("Lose 30 pounds in 90 days")
- Before-and-after content that presents outlier results without a "results not typical" disclosure
- "Clinically proven to…" when citing studies on brand-name drugs to imply your compounded product is proven
- Testimonials with specific numbers unless those numbers reflect typical outcomes
Violation #3: Implied FDA Approval of Compounded Drugs
This violation is often unintentional — brands don't explicitly say "FDA-approved," but they use language that allows consumers to infer it. The FDA takes a broad view of what constitutes an implied approval claim.
Even without saying "FDA-approved," this combination of phrases creates the impression of regulatory endorsement. "FDA-compliant ingredients" suggests the product itself has passed FDA review. "Clinically tested" without citing specific trials implies the product has been studied in the same way that approved drugs have.
The required disclosure — that compounded drugs are not FDA-approved — must appear prominently on pages where the product is promoted. Burying it in fine print or on a separate legal page is not sufficient. The FDA has specifically cited cases where the disclosure was present but not "clearly and conspicuously" placed.
Violation #4: Disease Claims Without Drug Approval
This is the one most brands recognize from standard supplement compliance — disease claims are only permitted for FDA-approved drugs, not for unapproved products. The wrinkle with GLP-1s is that some compounded semaglutide and tirzepatide products are marketed for both weight management and type 2 diabetes, even though compounded versions are not approved for either indication.
Making explicit diabetes treatment claims for a compounded drug that is not FDA-approved for that indication is a clear violation. Even if the underlying molecule (semaglutide) is approved for diabetes in its brand-name form, the compounded version does not inherit that approval. Marketing it for diabetes treatment misbrands the product.
Related patterns to watch for:
- Cardiovascular claims ("reduces heart disease risk") — even though brand-name semaglutide has some CV data, your compounded product does not
- PCOS, fatty liver, or metabolic syndrome claims
- Implied disease treatment in testimonials ("My A1C dropped from 9.2 to 5.8")
Violation #5: Missing or Buried Disclosures
Multiple 2026 warning letters cited not the absence of disclosures, but their placement. The FDA and FTC have both signaled that disclosures must appear at the point where claims are made — not at the bottom of a long page after a conversion event has already occurred.
If your hero section says "Lose weight with prescription GLP-1s" and the disclosure that these are compounded, unapproved drugs appears 2,000 pixels below the fold, regulators will treat the disclosure as functionally absent. The corrective claim and the disclosure need to travel together.
Required disclosures for compounded GLP-1 marketing typically include:
- The product is a compounded medication, not an FDA-approved drug
- A prescription is required
- Individual results vary
- State availability limitations (if applicable)
- That the program involves a clinician evaluation before any medication is prescribed
The FTC Healthcare Task Force: A Second Front
The FDA isn't working alone. In March 2026, the FTC launched a dedicated Healthcare Task Force with an explicit mandate to investigate deceptive practices in telehealth, digital health, and pharmaceutical marketing. This adds a second, independent enforcement body with its own tools — civil penalties, injunctions, and consumer redress requirements — that operates in parallel to FDA warning letters.
The FTC's primary concerns in the GLP-1 space include:
- Deceptive pricing and subscription terms — hidden auto-renewals, unclear cancellation terms, and price-lock promises that aren't honored
- Misleading before-and-after advertising — the FTC's updated endorsement guidelines require that results in advertising reflect what consumers will typically achieve, not outliers
- Fake urgency and scarcity tactics — countdown timers, "limited supply" claims, and "price increasing soon" language that misrepresents real availability
- Undisclosed paid endorsements — including influencer partnerships and patient testimonials that are compensated
A single marketing page can simultaneously violate FDA drug marketing rules (triggering a warning letter) and FTC advertising standards (triggering an investigation or civil action). These are separate proceedings with separate penalties. Resolving one does not resolve the other.
Safe vs. Risky Claims: A Side-by-Side Guide
The following table summarizes the most common claim categories in GLP-1 marketing and shows the risk level alongside compliant alternatives.
| Claim Type | ⚠ Risky Phrasing | ✓ Compliant Alternative |
|---|---|---|
| Drug equivalence | "Same as Ozempic® — lower price" | "Compounded GLP-1 program prescribed by licensed clinicians" |
| Weight loss outcome | "Lose 20 lbs in 60 days — guaranteed" | "Clinical studies show significant average weight loss. Results vary by individual." |
| FDA approval | "FDA-compliant, clinically tested medication" | "Compounded medications are not FDA-approved drugs. Prescription required." |
| Disease treatment | "Treat type 2 diabetes with GLP-1" | "Ask your clinician if GLP-1 therapy may be appropriate for your health goals" |
| Drug labeling | "Generic semaglutide" or "Biosimilar" | "Compounded semaglutide" (with not-FDA-approved disclosure) |
| Testimonials | "I reversed my diabetes!" — [Name] | Include: "Individual results vary. This is not a typical result. Not a testimonial from a compensated reviewer." [if paid] |
| Urgency tactics | "Offer ends tonight — price going up!" | Use urgency only when it reflects real, verifiable conditions |
How to Audit Your GLP-1 Marketing Today
If you're running a GLP-1 program, the following checklist covers the highest-risk areas based on 2026 warning letter patterns. Work through every page where your product is marketed.
Homepage and Landing Pages
- Remove all brand-name comparisons ("same as Ozempic," "like Wegovy," "generic Mounjaro")
- Ensure the not-FDA-approved disclosure appears above the fold or immediately adjacent to primary claims — not only in the footer
- Verify that outcome numbers (if used) come from peer-reviewed published studies and are cited with a footnote
- Confirm that "guaranteed" language has been removed unless you have a refund policy that can support the claim
Testimonials and Before/After Content
- Add "Individual results vary" to every testimonial
- If the testimonial-giver was compensated (free product, discount, payment), add a disclosure: "[Name] received our service at no cost in exchange for this review"
- Remove any testimonial that contains disease treatment claims (A1C changes, blood sugar improvements)
Paid Ads
- Audit all active ad copy for sameness claims and specific outcome guarantees
- Ensure that landing pages linked from ads contain the same disclosures required on organic pages — not a stripped-down version
- Check that ad creative doesn't contain before/after imagery that implies typical results
Email Campaigns
- Review promotional sequences for disease claims or implied FDA approval
- Confirm that unsubscribe mechanisms are working and comply with CAN-SPAM
- Ensure that promotional emails to non-patients don't contain prescription drug claim language
Don't just audit the page as it renders — also review the page source for any hidden text, image alt tags with claim language, or meta descriptions that make claims. Regulators have cited all of these in past enforcement actions.
Scan Your GLP-1 Marketing in Minutes
ScanCompliant automatically flags sameness claims, unsubstantiated outcomes, implied approval language, missing disclosures, and disease claims across your entire website — without you having to read every line manually.
Start Free — 5 Days, No Credit CardCovers websites, landing pages, and blog content. Results in under 15 minutes.
GLP-1 marketing compliance isn't a one-time project. The regulatory environment is evolving, new enforcement letters establish new expectations, and your marketing copy changes constantly. A review you did six months ago may not reflect what's on your site today after a round of A/B testing, new landing pages, or an agency refresh.
The brands that avoid enforcement actions in this environment are the ones treating compliance as an ongoing process — not a checkbox they completed at launch. Build compliance review into your standard content workflow, the same way you'd have a medical or legal reviewer sign off on clinical claims before they go live.